Title |
Acquired resistance to cancer immunotherapy
|
---|---|
Published in |
Seminars in Immunopathology, July 2018
|
DOI | 10.1007/s00281-018-0692-y |
Pubmed ID | |
Authors |
Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness, Marco Donia |
Abstract |
In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Denmark | 3 | 60% |
United Kingdom | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 40% |
Scientists | 2 | 40% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 60 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 18% |
Student > Master | 7 | 12% |
Student > Ph. D. Student | 6 | 10% |
Student > Bachelor | 5 | 8% |
Student > Postgraduate | 4 | 7% |
Other | 7 | 12% |
Unknown | 20 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 11 | 18% |
Immunology and Microbiology | 10 | 17% |
Medicine and Dentistry | 8 | 13% |
Agricultural and Biological Sciences | 4 | 7% |
Environmental Science | 1 | 2% |
Other | 4 | 7% |
Unknown | 22 | 37% |